KWON, Se Chang,JUNG, Sung Youb,KIM, Jung Kuk,HEO, Yong Ho,KIM, Dae Jin,CHOI, In Young
申请号：
PE2016002386
公开号：
PE20170195A1
申请日:
2015.05.29
申请国别(地区):
PE
年份:
2017
代理人:
摘要：
The current invention refers to an integral part of diabetes prevention or treatment, including a hybrid action insulin analysis and a combination of long-term action insulin. More specifically, the combination of long-term movement analysis and hyperinsulinemic displacement inhibited the increased weight due to insulin intake, as well as the vomiting and nausea due to insulin insulin intake, and also reduced the required dose. Insulin was injected, which greatly improved compliance with pharmacists. Besides,The current invention is a pharmacological synthesis for reducing the side effects of insulin cells in diabetic patients, including a long-acting insulin analysis combination and a long-acting insulin comprehensive analysis combination, There is also a way to reduce the side effects of pancreatic cells in diabetic patients, including the stage of cell composition control. In particular, the current invention is characterized by the reduction of side effects, such as pancreatic cancer cell dysfunction related to the development of diabetes,Pancreatin B cell quality decline, fat or glucose poisoningLa presente invencion se refiere a una composicion para la prevencion o tratamiento de la diabetes que incluye un conjugado de analogo de insulina de accion prologada y un conjugado de peptido insulinotropico de accion prolongada. Mas especificamente, la administracion de la combinacion del conjugado de analogo de accion prolongada y el conjugado de peptido insulinotropico de accion prolongada, inhibe el aumento de peso debido a la administracion de insulina, y los vomitos y nauseas debidos a la administracion del peptido insulinotropico, y tambien reduce la dosis requerida de insulina, mejorando notablemente de esta forma la observancia del farmaco. Ademas, la presente invencion se refiere a la administracion de una composicion farmaceutica para reducir efectos secundarios de las celulas beta pancreaticas en pacientes diabeticos, que incluye un conjugado de analogo de
